Decitabine

Anemia, Anemia, Refractory, Anemia + 6 more
Treatment
20 Active Studies for Decitabine

What is Decitabine

DecitabineThe Generic name of this drug
Treatment SummaryGuadecitabine is a medication being studied as a treatment option for colorectal cancer that has not responded to other treatments.
Dacogenis the brand name
image of different drug pills on a surface
Decitabine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Dacogen
Decitabine
1996
36

When to interrupt dosage

The suggested measure of Decitabine is contingent upon the determined affliction. The amount of dosage may differ, in accordance with the technique of administration featured in the table beneath.
Condition
Dosage
Administration
Anemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet - Oral, Tablet
Anemia, Refractory
, 5.0 mg/mL, 50.0 mg, 35.0 mg
Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet - Oral, Tablet
Anemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet - Oral, Tablet
Chronic Myelomonocytic Leukemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet - Oral, Tablet
Myelodysplastic Syndrome
, 5.0 mg/mL, 50.0 mg, 35.0 mg
Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet - Oral, Tablet
Anemia
, 5.0 mg/mL, 50.0 mg, 35.0 mg
Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet - Oral, Tablet
IPSS High Risk
, 5.0 mg/mL, 50.0 mg, 35.0 mg
Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet - Oral, Tablet
Myelodysplastic Syndromes
, 5.0 mg/mL, 50.0 mg, 35.0 mg
Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet - Oral, Tablet
Myelodysplastic Syndromes
, 5.0 mg/mL, 50.0 mg, 35.0 mg
Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, , Intravenous, Injection, powder, for solution - Intravenous, Injection, powder, for solution, Injection, Injection - Intravenous, Powder - Intravenous, Powder, Tablet, film coated - Oral, Tablet, film coated, Oral, Tablet - Oral, Tablet

Warnings

There are 20 known major drug interactions with Decitabine.
Common Decitabine Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Decitabine is combined with Acteoside.
image of a doctor in a lab doing drug, clinical research

Decitabine Novel Uses: Which Conditions Have a Clinical Trial Featuring Decitabine?

No active trials are currently assessing Decitabine's potential to address unspecified medical conditions.
Condition
Clinical Trials
Trial Phases
Myelodysplastic Syndrome
127 Actively Recruiting
Phase 1, Phase 2, Phase 3, Not Applicable, Phase 4
Chronic Myelomonocytic Leukemia
54 Actively Recruiting
Phase 1, Phase 2, Phase 3, Early Phase 1
Anemia
0 Actively Recruiting
Anemia
0 Actively Recruiting
Anemia
0 Actively Recruiting
Anemia, Refractory
0 Actively Recruiting
IPSS High Risk
0 Actively Recruiting
Myelodysplastic Syndromes
0 Actively Recruiting
Myelodysplastic Syndromes
0 Actively Recruiting

Decitabine Reviews: What are patients saying about Decitabine?

5Patient Review
1/14/2010
Decitabine for Bone Marrow Disorders Occurring Before Leukemia
This is a test review.
3.7Patient Review
10/31/2010
Decitabine for Bone Marrow Disorders Occurring Before Leukemia
The first week of treatment caused me to lose some appetite and itch my head, which then developed into a rash on my stomach. Otherwise, the treatment was okay. I have two more treatments scheduled, for a total of seven.
3.7Patient Review
11/10/2009
Decitabine for Bone Marrow Disorders Occurring Before Leukemia
After my bone marrow test revealed pre-leukemia, I had two rounds of treatment (five days in one week's time) once a month in July and August 2009 (10 IV's!). I then developed a severe infection and was hospitalized for nine days. After recovering from the infection, I received packed cells and some transfusions during this time. I am now in remission! My blood work has been checked for September/October/ and part of November 2009 and all counts are up. So far, so good!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about decitabine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is decitabine a chemotherapy drug?

"DECITABINE is a chemotherapy drug that helps to reduce the growth of cancer cells. It is most often used to treat adults who have myelodysplastic syndromes."

Answered by AI

How long does it take decitabine to work?

"The median time for patients to achieve some level of remission for either CR or CRh was 2 months."

Answered by AI

What does decitabine treat?

"It works by decreasing the abnormal cells in the bone marrow. This helps the bone marrow to make healthy blood cells.

This drug is used to manage a number of conditions that impact the blood and bone marrow (myelodysplastic syndromes-MDS), in which the bone marrow does not produce a sufficient amount of healthy blood cells. People with MDS may experience issues such as infections, anemia, and easy bleeding/bruising. Decitabine is a chemotherapy drug that works by reducing the amount of abnormal cells in the bone marrow. This, in turn, helps the bone marrow to produce healthy blood cells."

Answered by AI

What class of drug is decitabine?

"Decitabine is a medication used to help the bone marrow produce normal blood cells, and to kill abnormal cells in the bone marrow."

Answered by AI

Clinical Trials for Decitabine

Image of The University of Arizona Cancer Center in Tucson, United States.

DLI-X for Leukemia

Any Age
All Sexes
Tucson, AZ
The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo) hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. Additionally, the study aims to assess the safety and efficacy of therapeutic DLI-X (t-DLI-X) compared to t-DLI alone in patients with minimal residual disease (MRD+) or overt relapse post-alloHCT. For patients with CD19-positive lymphoid malignancies, the study will incorporate blinatumomab, while those with myeloid or CD19-negative lymphoid malignancies will receive t-DLI-X or t-DLI alone. We hypothesize that both pro-DLI-X and t-DLI-X, with or without blinatumomab, will demonstrate safety and superior efficacy by enhancing graft-versus-leukemia (GvL) effects mediated by natural killer (NK) cells, γδ T cells, and CD8+ T cells, while maintaining manageable and treatment-responsive graft-versus-host disease (GvHD).
Phase 1
Waitlist Available
The University of Arizona Cancer CenterEmmanuel Katsanis, MD
Image of OHSU Knight Cancer Institute in Portland, United States.

Fludarabine + Cytarabine + Idarubicin + Venetoclax for Acute Myeloid Leukemia

18 - 65
All Sexes
Portland, OR
This phase II trial compares induction and consolidation therapy with fludarabine, cytarabine, idarubicin, and venetoclax to cytarabine and daunorubicin induction and cytarabine consolidation for the treatment of acute myeloid leukemia (AML). Patients with AML often receive induction and consolidation therapy. Induction therapy is given first to get the patient's AML under control (remission). Consolidation therapy is given after the cancer has disappeared following the initial therapy. Consolidation therapy is used to kill any cancer cells that may be left in the body. Chemotherapy drugs, such as fludarabine, cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving fludarabine, cytarabine, idarubicin, and venetoclax for induction and consolidation therapy may be more effective in treating AML.
Phase 2
Waitlist Available
OHSU Knight Cancer InstituteCurtis A Lachowiez
Have you considered Decitabine clinical trials? We made a collection of clinical trials featuring Decitabine, we think they might fit your search criteria.Go to Trials
Image of Fred Hutch/University of Washington Cancer Consortium in Seattle, United States.

Combination Therapy for Acute Myeloid Leukemia

18+
All Sexes
Seattle, WA
This phase II trial tests the safety, side effects, and how well combination chemotherapy with fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor (G-CSF), and idarubicin (FLAG-Ida) followed immediately by reduced-intensity total body radiation therapy, called total body irradiation (TBI), and donor hematopoietic cell transplant (HCT) works in treating adults age 60 and older with newly diagnosed adverse-risk acute myeloid leukemia (AML) or other high-grade myeloid cancer. Despite advances in supportive care and the approval of more than 10 new drugs since 2017, the outcomes of older adults with adverse-risk acute myeloid leukemia and other high-grade myeloid cancers remains poor. Most patients are expected to die from their cancer or the consequences of treatment-related side effects. Donor HCT is a very important part of any curative-cancer treatment for these patients. However, while accepted as standard care for decades, this treatment exposes patients to long periods of drug-induced low blood cell counts and the problems associated with low blood counts, like infections and bleeding, which are associated with significant risk of chronic side effects and death. This study will use a different approach to the upfront curative-cancer treatment of older adults with an adverse-risk AML or other high-grade myeloid cancer. This study will use intense chemotherapy followed a few days later by lower-dose TBI and donor HCT. Chemotherapy drugs, such as idarubicin, fludarabine, high-dose cytarabine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. G-CSF helps the bone marrow make more white blood cells in patients with low white blood cell count due to cancer treatment. This approach allows effective treatment of cancer cells and overall reduction of the period of low blood cells counts. This decreases the risk for problems associated with low blood counts, such as infection and chronic side effects. Decreasing these are important for older adults who undergo HCT. This treatment strategy may improve treatment outcomes by allowing more patients to successfully undergo donor HCT and reduce the risk of low blood cell counts and the problems associated with low blood counts. Giving chemotherapy followed immediately by reduced-intensity TBI and donor HCT may be safe, tolerable and/or effective in treating adults age 60 and older with newly diagnosed adverse-risk AML or other high-grade myeloid cancer.
Phase 2
Recruiting
Fred Hutch/University of Washington Cancer ConsortiumFilippo Milano, MD, PhD
Image of City of Hope Medical Center in Duarte, United States.

CMV-MVA Triplex Vaccine for Cancer

18 - 75
All Sexes
Duarte, CA
This phase Ib trial tests the safety, side effects, and how well cytomegalovirus (CMV)-modified vaccinia Ankara (MVA) Triplex vaccine works in enhancing CMV-specific immunity and preventing CMV viremia in patients undergoing haploidentical hematopoietic stem cell transplant. Haploidentical stem cell transplantation (haploHCT) has advanced to become the predominant procedure for patients lacking a matched donor. Compared to matched related donor transplants, the rate of significant CMV infection is higher in patients undergoing a haploHCT. Significant CMV infection is associated with an increased risk of complications and death. Vaccination is the main preventative approach to limit complications and death in immunocompromised patients at high risk of post-stem cell transplant infections. CMV-MVA Triplex vaccine, is a CMV vaccine based on the attenuated poxvirus, modified vaccinia Ankara (MVA), developed to enhance CMV-specific immunity in both healthy stem cell transplant donors and stem cell transplant patients to prevent significant CMV infection post-stem cell transplant. Giving CMV-MVA triplex vaccine may be safe, tolerable and/or effective in enhancing cytomegalovirus (CMV)-specific immunity and preventing CMV viremia in patients undergoing a haploHCT.
Phase 1
Waitlist Available
City of Hope Medical Center (+2 Sites)Ryotaro Nakamura
Image of City of Hope Medical Center in Duarte, United States.

Emapalumab for Graft-versus-Host Disease

18 - 75
All Sexes
Duarte, CA
This phase I trial tests the safety, side effects and effectiveness of emapalumab with post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil in preventing graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after reduced-intensity donor (allogeneic) hematopoietic cell transplant (HCT). Giving chemotherapy, such as fludarabine, melphalan, or busulfan, before a donor \[peripheral blood stem cell\] transplant helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. When healthy stem cells for a donor are infused into a patient (allogeneic HCT), they may help the patient's bone marrow make more healthy cells and platelets. Allogeneic HCT is an established treatment, however, GVHD continues to be a major problem of allogeneic HCT that can complicate therapy. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Emapalumab binds to an immune system protein called interferon gamma. This may help lower the body's immune response and reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants. Mycophenolate mofetil is a drug used to prevent GVHD after organ transplants. It is also being studied in the prevention of GVHD after stem cell transplants for cancer, and in the treatment of some autoimmune disorders. Mycophenolate mofetil is a type of immunosuppressive agent. Giving emapalumab with post-transplant cyclophosphamide, tacrolimus and mycophenolate mofetil may be safe, tolerable and/or effective in preventing GVHD in patients with AML or MDS after a reduced-intensity allogeneic HCT.
Phase 1
Waitlist Available
City of Hope Medical CenterAmandeep Salhotra
Have you considered Decitabine clinical trials? We made a collection of clinical trials featuring Decitabine, we think they might fit your search criteria.Go to Trials
Image of Rare Disease Research in Atlanta, United States.

EPI-321 for Muscular Dystrophy

18 - 75
All Sexes
Atlanta, GA
The goal of this clinical trial is to learn how safe and tolerable EPI-321 is and whether there may be early signs it is working in male or female adult (18 to 75 years) participants with facioscapulohumeral muscular dystrophy (FSHD) Type 1 condition. The main questions it aims to answer are: How safe is EPI-321 and how well can people handle it over time? How does EPI-321 interact with its target and does it show early signs of working? Participants will receive a single dose of EPI-321 through a vein while being closely watched in a hospital and visit the clinic regularly for tests and checkups for about 5 years after getting EPI-321.
Phase 1 & 2
Recruiting
Rare Disease Research (+3 Sites)Epicrispr Biotechnologies, Inc.
Image of MD Anderson in Houston, United States.

Cyclophosphamide-Based Prophylaxis for Leukemia

18 - 66
All Sexes
Houston, TX
The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The source of stem cells is from someone who is not related and has a different blood cell type than the study participant. The researchers will compare the new drug combination to a standard drug combination. They will also learn about the safety of each drug combination. Participants will: * Receive the standard or new drug combination after transplant * Visit the doctor's office for check-ups and tests after transplant that are routine for most transplant patients * Take surveys about physical and emotional well-being * Give blood and stool samples.
Phase 2
Recruiting
MD Anderson (+2 Sites)Incyte Corporation
Image of Children's Hospital of Philadelphia in Philadelphia, United States.

CD45RA Depleted Stem Cell Addback for Leukemia

1 - 25
All Sexes
Philadelphia, PA
The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections. T cell receptor alpha beta (TCRαβ) T lymphocyte depletion and CD19+ B lymphocyte depletion of alternative donor hematopoietic stem cell (HSC) grafts is effective in preventing GVHD, but immune reconstitution may be delayed, increasing the risk of infections. The central hypothesis of this study is that an addback of CD45RO memory T lymphocytes, derived from a fraction of the original donor peripheral stem cell product depleted of CD45RA naïve T lymphocytes, will accelerate immune reconstitution and help decrease the risk of infections in TCRab/CD19 depleted PSCT.
Phase 1 & 2
Recruiting
Children's Hospital of PhiladelphiaTimothy Olson, MD, PhD
Image of City of Hope Medical Center in Duarte, United States.

Vedolizumab + Cyclophosphamide + Tacrolimus for Graft-versus-Host Disease

18 - 80
All Sexes
Duarte, CA
This phase II trial studies how well vedolizumab plus post-transplant cyclophosphamide (PTCy) and short course tacrolimus work for the prevention of graft versus host disease (GVHD) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) after reduced intensity conditioning. Allogeneic HCT is a procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a donor. Giving reduced conditioning chemotherapy before an allogeneic HCT helps kill cancer cells in the body and helps make room in the patient's bone marrow for new stem cells to grow using less than standard doses of chemotherapy. Sometimes, the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Vedolizumab is a monoclonal antibody, which is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). It may reduce inflammation. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid and may kill cancer cells. It may also lower the body's immune response. Tacrolimus suppresses the immune system by preventing the activation of certain types of immune cells. Giving vedolizumab plus PTCy and short course tacrolimus may be effective at preventing GVHD after allogeneic HCT.
Phase 2
Recruiting
City of Hope Medical CenterMonzr M. Al Malki
Have you considered Decitabine clinical trials? We made a collection of clinical trials featuring Decitabine, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security